Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. by Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Leppä, S

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. by Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppä, S

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas by Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppa, S

Association between anthropometry and lifestyle factors and risk of B‐cell lymphoma: an exposome‐wide analysis by Saberi Hosnijeh, F, Casabonne, D, Nieters, A, Solans, M, Naudin, S, Ferrari, P, Mckay, JD, Benavente, Y, Weiderpass, E, Freisling, H, Severi, G, Boutron Ruault, M-C, Besson, C, Agnoli, C, Masala, G, Sacerdote, C, Tumino, R, Huerta, JM, Amiano, P, Rodriguez-Barranco, M, Bonet, C, Barricarte, A, Christakoudi, S, Knuppel, A, Bueno-de-Mesquita, B, Schulze, MB, Kaaks, R, Canzian, F, Späth, F, Jerkeman, M, Rylander, C, Tjønneland, A, Olsen, A, Borch, KB, Vermeulen, R